Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03243383 · ClinicalTrials.gov registry record · NA
Readmission Prevention Pilot Trial in Diabetes Patients
A NA study, sponsored by Temple University.
- Completed
- Registry status
- NA
- Development phase
- 263
- Enrollment target
NCT03243383 is a NA study that has completed, run by Temple University. The registered enrollment target is 263 participants.
The verdict
NCT03243383, a NA study, has completed, sponsored by Temple University.
- COMPLETED
- Registry status
- NA
- Development phase
- 263 participants
- Enrollment target
Study Summary
Post-discharge hospital utilization, i.e., readmissions within 30 days of discharge (30d readmissions) and emergency department (ED) visits, are a high-priority quality measure and target for cost reduction. Patients with diabetes are disproportionately over-represented in 30d readmissions, especially among racial minorities and urban populations. We have developed and validated a tool, the Diabetes Early Readmission Risk Indicator (DERRI), to predict 30d readmission risk among diabetes patients, which is a critical prerequisite for targeting limited resources for reducing readmission risk to those most in need. Currently, there are no proven interventions to reduce the risk of 30d readmission specifically among patients with diabetes. This proposal will assess the feasibility and acceptability of a novel, multifactorial intervention, the Diabetes Transition of Hospital Care Program (DiaTOHC), designed to reduce post-discharge hospital utilization rates in a pilot randomized controlled trial. The intervention will include inpatient diabetes and discharge education, comprehensive discharge planning and coordination of care, A1c-based adjustment of diabetes therapy, and post-discharge support. Hospitalized patients with diabetes identified as high risk for readmission based on the DERRI will be randomized to the intervention or the control group, which will receive usual care. Such work is highly relevant in the current era of soaring health care costs and national health care reform.
Interventions
- OTHER DiaTOHC Program
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 263 participants |
| Start Date | 2017-09-07 |
| Est. Completion | 2019-10-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03243383
The ClinicalTrials.gov registry entry for NCT03243383 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 263 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Temple University, which has 163 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DiaTOHC Program is the first listed.
NCT03243383 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03243383 about?
NCT03243383 is a clinical study titled "Readmission Prevention Pilot Trial in Diabetes Patients". Post-discharge hospital utilization, i.e., readmissions within 30 days of discharge (30d readmissions) and emergency department (ED) visits, are a high-priority quality measure and target for cost reduction. Patients with diabetes are disproportionately over-represented in 30d readmissions, especial...
What is the current status of trial NCT03243383?
This trial is currently completed. It is a NA study. The enrollment target is 263 participants. The study started on 2017-09-07. Estimated completion is 2019-10-01.
What interventions are being tested in trial NCT03243383?
The interventions under investigation include: DiaTOHC Program (OTHER).
Who is sponsoring clinical trial NCT03243383?
This trial is sponsored by Temple University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.